Update on the group's business
Update on the group's businessEARNINGS/SALES RELEASES
FACT
Crossject released H1 20 results. Revenues reached €2,086k (vs €1,844k), operating result €-5,632k (vs €-5,873k), and net result €-5,258k (vs €-4,953k). Net cash at the end of H1 20 was €-1.3m (vs €1.5m) and €1.8m at the end of FY19.
ANALYSIS
As always, the results as such are surprise-free and not very important since no product has reached the market yet, except for the cash-burn (ex new financing) which was limited to €4.6m, a “decent” number.
Compared to H1 19, no turnover was achieved (keeping in mind that last year saw turnover reaching €0.5m, after the agreement with German Desitin on the licensing, distribution and promotion, until 10 years after commercial launch, of Zeneo Midazolam in Germany). The company also indicated that the calendar for the product filings is unclear, given the uncertainties having emerged due to the pandemic (with Midazolam and Adrenaline still as the first candidates in our understanding). However, the production of batches has resumed in May, which is good news for the group. On the P&L front, it is worth mentioning that external charges were well under control (-16% to €2.6m) due to the decrease in external staffing and a tight control of inventories. As a result, and despite the increase in in-house staff (+16 to 88, mainly in production and technical development), the operating result was almost flat year-on-year, “only” down from €-5.3m to €-5.9m. In terms of financing, the group asserts it is expecting the signature of licences with upfront fees as well as further undetailed incentives, also reminding that the company is still working on long-term options, with a priority put on non-dilutive ones. The group also indicates that its US subsidiary is now actively promoting partnerships and increasing the group’s presence with health institutions.
IMPACT
No big change to our numbers or valuation to be expected after this release. Our valuation is, of course, based on the various product launches to take place in the years to come and not on current numbers. Any change can therefore only stem from news/facts on that front. Although the exact timing of filings (and subsequent launches) is unknown, we remain confident and acknowledge the progress the company is making to reach its goals.
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.